HPLC SERUM ANALYSES WITHOUT PRIOR PROTEIN REMOVAL

DRUGS NOW DETERMINED IN SERUM-HUNDREDS OF THOUSANDS OF SAMPLES PER YEAR IN THE UNITED STATES ALONE-BY HIGH-PRESSURELIQUID CHROMATOGRAPHY (HPLC). PROTEIN MUST FIRST BE REMOVEDFROM THE SERUM, OTHERWISE THE HPLC COLUMNS ARE QUICKLY RUINED. INTERNAL-SURFACE REVERSED-PHASE (ISRP) HPLC COLUMNSAFFORD SUCH DETERMINATIONS WITHOUT REQUIRING THE PRIOR REMOVAL OF PROTEIN FROM THE SERUM. WITH PHASE I ASSISTANCE,REGIS SYNTHESIZED THE FIRST COMMERCIAL ISRP, GLYCINE- PHENYLALANINE-PHENYLALANINE (GFF); PUT ITS SYNTHESIS ON A PRODUCTION BASIS; CHARACTERIZED GFF; BROUGHT REPRODUCIBLE, EFFICIENT, LONG-LIVED, AND SELECTIVE GFF ISRP HIGH- EFFICIENCY HPLC COLUMNS TO MARKET; DEMONSTRATED SEVERAL REAL-LIFE ISRP GFF APPLICATIONS; AND PUBLICIZED THE EFFORT IN A VARIETY OF WAYS. WITH PHASE II ASSISTANCE, REGIS WILL DEVELOP FURTHER DEMONSTRATIVE APPLICATIONS OF GFF AND RE- STUDY THE SYNTHESIS SO AS TO PRODUCE BETTER SUCCESSORS. COMPLEMENTARY ISRPS WILL THEN BE SYNTHESIZED, CHARACTERIZED,INTRODUCED, AND SUPPORTED. ALSO, CONCEPTUALLY NEW ISRPS WILL BE SYNTHESIZED FOR APPLICATIONS NOW BEYOND ROUTINE REACH; ISRPS THAT AFFORD CHIRAL SEPARATIONS FREE-DRUG VERSUSBOUND-DRUG DETERMINATIONS, AND PREPARATIVE SEPARATIONS FOR BIOTECHNOLOGY.